

Ref. No: 2786
Date: 08/09/26
Subject: Derm and Rheum New Patients

REQUEST

Q1. How many new patients were treated for any condition by the Trust's Dermatology Department in the latest 3-month period of April, May and June 2026 (or the latest 3 months available) with the treatments I have provided below?

If you are able to, could you please provide the split of new patients who received their treatment for Psoriasis.

Please can you define a "new patient" as a patient who is receiving any of the treatments listed below for the first time. If a patient received any of the below treatments in 2024 or previous years, they can be classed as a new patient for this period.

	Total Dermatology Department	Psoriasis
Adalimumab [Humira]		
Adalimumab [All Biosimilars]		
Apremilast [Otezla]		
Apremilast [Generic]		
Etanercept [Enbrel]		
Etanercept [All Biosimilars]		
Infliximab [Remicade]		
Infliximab [All Biosimilars]		
Ustekinumab [Stelara]		
Ustekinumab [All Biosimilars]		
Bimekizumab [Bimzelx]		
Brodalumab [Kyntheum]		
Certolizumab [Cimzia]		
Deucravacitinib [Sotyktu]		
Dimethyl Fumarate [Skilarence]		
Guselkumab [Tremfya]		
Ixekizumab [Taltz]		
Risankizumab [Skyrizi]		
Secukinumab [Cosentyx]		

Spesolimab [Spevigo]		
Tildrakizumab [illumetri]		

Q2. How many new patients were treated for any condition by the Trust's Rheumatology Department in the latest 3-month period of April, May and June 2026 (or the latest 3 months available) with the treatments I have provided below?

If you are able to, could you please provide the split of new patients who received their treatment for Axial Spondyloarthritis (axSpA), Rheumatoid Arthritis (RA) and Psoriatic Arthritis (PsA).

	Total Rheumatology Department	Axial Spondyloarthritis (axSpA)	Rheumatoid Arthritis (RA)	Psoriatic Arthritis (PsA)
Abatacept [Orencia]				
Adalimumab [Humira]				
Adalimumab [All Biosimilars]				
Apremilast [Otezla]				
Apremilast [Generic]				
Baricitinib [Olumiant]				
Bimekizumab [Bimzelx]				
Certolizumab [Cimzia]				
Etanercept [Enbrel]				
Etanercept [All Biosimilars]				
Filgotinib [Jyseleca]				
Golimumab [Simponi]				
Golimumab [All Biosimilars]				
Guselkumab [Tremfya]				
Infliximab [Remicade]				
Infliximab [All Biosimilars]				
Ixekizumab [Taltz]				
Risankizumab [Skyrizi]				
Rituximab [MabThera]				
Rituximab [Biosimilars]				
Sarilumab [Kevzara]				
Secukinumab [Cosentyx]				
Tocilizumab [RoActemra]				
Tocilizumab [Biosimilars]				
Tofacitinib [Xeljanz]				
Upadacitinib [Rinvoq]				
Ustekinumab [Stelara]				

RESPONSE

Following a thorough assessment, we regret to inform you that Mersey and West Lancashire Teaching Hospitals NHS Trust is unable to comply with your request, as doing so would exceed the cost limit set out under Section 12 of the Freedom of Information Act 2000.

Section 12 states that a public authority is not obliged to comply with a request for information if it estimates that the cost of doing so would exceed the appropriate limit, which is currently set at £450 for NHS organisations. This equates to 18 hours of staff time, calculated at a standard rate of £25 per hour, as defined in the Freedom of Information and Data Protection (Appropriate Limit and Fees) Regulations 2004.

In this case, fulfilling your request would require checking individual patients records and the Trust has estimated this time to be in excess of 505 hours. This involves locating, retrieving, and extracting the relevant information. This exceeds the 18-hour threshold, even with reasonable efforts to narrow the scope.

We are therefore applying Section 12 of the Act and will not be proceeding with the request in its current form.